FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases

Key facts

Sponsor

xCures

Principal Investigator

Mark Shapiro, MS

Enrollment

1000 enrolled

Eligibility

All sexes

Timeline

2024 – 2026

Study locations (1)

• xCures, Los Altos, California, United States

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Other trials for Alpha-thalassemia

Additional recruiting or active studies for the same condition.

• RECRUITINGNCT06591936
  Genetic Profile of Alpha Thalassemia Children at Sohag University Hospital .
  Sohag University
• RECRUITINGEARLY PHASE1NCT06107400
  Safety and Efficacy of RM-004 Cells for Hemoglobin H-Constant Spring Disease
  The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army
• RECRUITINGPHASE2NCT05664737
  A Study to Determine the Efficacy and Safety of Luspatercept in Adult Participants and to Evaluate the Safety and Pharmacokinetics in and Adolescent Participants With Alpha (α)-Thalassemia
  Bristol-Myers Squibb
• ACTIVE NOT RECRUITINGPHASE3NCT04770753
  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)
  Agios Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGPHASE3NCT04770779
  A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-TDT)
  Agios Pharmaceuticals, Inc.
• ACTIVE NOT RECRUITINGNANCT02692872
  Screening for Alpha Thalassemia in Healthy Volunteers
  National Institute of Allergy and Infectious Diseases (NIAID)
• RECRUITINGNCT04872179
  International Registry of Patients With Alpha Thalassemia
  University of California, San Francisco

See all trials for Alpha-thalassemia →